Patents Assigned to Pherin Pharmaceuticals, Inc.
-
Patent number: 11419881Abstract: 16?,17?-Epoxy-10?-hydroxyestr-4-en-3-one is useful in the treatment of migraine by nasal administration.Type: GrantFiled: April 7, 2020Date of Patent: August 23, 2022Assignee: Pherin Pharmaceuticals, Inc.Inventor: Louis Monti
-
Publication number: 20200323884Abstract: 16?,17?-Epoxy-10?-hydroxyestr-4-en-3-one is useful in the treatment of migraine by nasal administration.Type: ApplicationFiled: April 7, 2020Publication date: October 15, 2020Applicant: Pherin Pharmaceuticals, Inc.Inventor: Louis Monti
-
Patent number: 10322138Abstract: Pregn-4-en-20-yn-3?-one is useful in the treatment of depressive disorders by nasal administration.Type: GrantFiled: December 19, 2013Date of Patent: June 18, 2019Assignee: PHERIN PHARMACEUTICALS, INC.Inventor: Louis Monti
-
Publication number: 20140187524Abstract: Pregn-4-en-20-yn-3?-one is useful in the treatment of depressive disorders by nasal administration.Type: ApplicationFiled: December 19, 2013Publication date: July 3, 2014Applicant: PHERIN PHARMACEUTICALS, INC.Inventor: LOUIS MONTI
-
Patent number: 8722652Abstract: Methods and compositions for the treatment of social phobia are provided, including administering a therapeutically effective amount of an androsta-4,16-dien-3-ol steroid to an individual in need of treatment and a pharmaceutical composition for the treatment of social phobia having a therapeutically effective amount of an androsta-4,16-dien-3-ol steroid. Therapeutically effective amounts may be, for example, between about 100 picograms and about 100 micrograms, or between about 1 nanogram and about 10 microgram, or between about 10 nanograms and about 1 microgram of an androsta-4,16-dien-3-ol steroid. Administration of the androsta-4,16-dien-3-ol compound is preferably intranasal administration to the nasal passages and the vomeronasal organ of the individual. A preferred androsta-4,16-dien-3-ol steroid is [3?]-androsta-4,16-dien-3-ol.Type: GrantFiled: August 13, 2012Date of Patent: May 13, 2014Assignee: Pherin Pharmaceuticals, Inc.Inventor: Louis Monti-Bloch
-
Patent number: 8431559Abstract: 16?,17?-Epoxy-10?-hydroxyestr-4-en-3-one is useful in the treatment of hot flashes by vomeronasal administration.Type: GrantFiled: November 3, 2011Date of Patent: April 30, 2013Assignee: Pherin Pharmaceuticals, Inc.Inventor: Louis Monti
-
Patent number: 8309539Abstract: Methods and compositions for the treatment of social phobia are provided, including administering a therapeutically effective amount of an androsta-4,16-dien-3-ol steroid to an individual in need of treatment and a pharmaceutical composition for the treatment of social phobia having a therapeutically effective amount of an androsta-4,16-dien-3-ol steroid. Therapeutically effective amounts may be, for example, between about 100 picograms and about 100 micrograms, or between about 1 nanogram and about 10 microgram, or between about 10 nanograms and about 1 microgram of an androsta-4,16-dien-3-ol steroid. Administration of the androsta-4,16-dien-3-ol compound is preferably intranasal administration to the nasal passages and the vomeronasal organ of the individual. A preferred androsta-4,16-dien-3-ol steroid is [3?]-androsta-4,16-dien-3-ol.Type: GrantFiled: September 9, 2005Date of Patent: November 13, 2012Assignee: Pherin Pharmaceuticals, Inc.Inventor: Louis Monti-Bloch
-
Publication number: 20090258040Abstract: Embodiments of the invention relate to methods for treating individuals suffering from hot flashes by vomeronasally administering a therapeutically effective dosage of a steroid agent. The hot flashes may be a result of postmenopause or castration suffered by the individual. In many embodiments, the method for treating individuals suffering with hot flashes is provided by administering a steroid agent containing an estrene compound, such as 16?,17?-epoxy-10?-hydroxyestr-4-en-3-one, to the individual. In other embodiments, pharmaceutical compositions containing the steroid agent may be used to treat individuals suffering with hot flashes. Embodiments include methods for treating male castrates, as well as postmenopausal women and men, suffering from hot flashes by vomeronasally administering a steroid agent containing 16?,17?-epoxy-10?-hydroxyestr-4-en-3-one to levitate the hot flashes.Type: ApplicationFiled: April 9, 2009Publication date: October 15, 2009Applicant: PHERIN PHARMACEUTICALS, INC.Inventor: Louis Monti
-
Patent number: 7087430Abstract: This invention relates to DNA libraries, in particular a human VNO cDNA library is described. Pheromone receptor cDNA once isolated is transfected into competent cells. The transfected cell lines provide a scaleable source of homogeneous material to develop efficient, automated high throughput screening assays for new vomeropherins, and thereby reduce the ongoing need for human volunteers in the preclinical phases of drug discovery. Identification and characterization of the human VNO receptor(s) will facilitate the development and commercialization of vomeropherins with improved specificity, and enhanced therapeutic efficacy in the treatment of the target diseases.Type: GrantFiled: June 12, 2003Date of Patent: August 8, 2006Assignee: Pherin Pharmaceuticals, Inc.Inventors: Ronald C. Herman, David L. Berliner
-
Publication number: 20030224440Abstract: This invention relates to DNA libraries, in particular a human VNO cDNA library is described. Pheromone receptor cDNA once isolated is transfected into competent cells. The transfected cell lines provide a scaleable source of homogeneous material to develop efficient, automated high throughput screening assays for new vomeropherins, and thereby reduce the ongoing need for human volunteers in the preclinical phases of drug discovery. Identification and characterization of the human VNO receptor(s) will facilitate the development and commercialization of vomeropherins with improved specificity, and enhanced therapeutic efficacy in the treatment of the target diseases.Type: ApplicationFiled: June 12, 2003Publication date: December 4, 2003Applicant: Pherin Pharmaceuticals, Inc.Inventors: Ronald C. Herman, David L. Berliner
-
Publication number: 20030220309Abstract: 17-Methylenandrostan-3&agr;-ol analogs are useful as corticotropin releasing hormone (CRH) inhibitors, and especially as anti-depressants, when administered to the vomeronasal organ. An improved synthesis of 17-methylenandrost-4-en-3&agr;-ol is disclosed.Type: ApplicationFiled: June 13, 2003Publication date: November 27, 2003Applicant: Pherin Pharmaceuticals, Inc.Inventors: Louis Monti, David L. Berliner, Clive L. Jennings-White, Nathan W. Adams
-
Patent number: 6555531Abstract: Pregnanes of formula I, and pharmaceutical compositions and products containing them, are useful in weight promotion by administration to the vomeronasal organ.Type: GrantFiled: December 30, 1999Date of Patent: April 29, 2003Assignee: Pherin Pharmaceuticals, Inc.Inventors: David L. Berliner, Louis Monti, Clive L. Jennings-White
-
Patent number: 6544971Abstract: A method of increasing alertness in an individual by administering an effective amount of an alertness-increasing vomeropherin to the individual; and an alarm device that, when activated, emits an alertness-increasing vomeropherin. The method and device are especially useful in increasing alertness in individuals who are not readily responsive to usual external stimuli.Type: GrantFiled: February 4, 2000Date of Patent: April 8, 2003Assignee: Pherin Pharmaceuticals, Inc.Inventors: David L. Berliner, Louis Monti, Clive L. Jennings-White
-
Patent number: 6352980Abstract: The invention relates to estrene steroids, which bind to neuroepithelial receptors. The steroid is preferably administered in the form of a pharmaceutical composition containing one or more pharmaceutically acceptable carriers.Type: GrantFiled: September 21, 1999Date of Patent: March 5, 2002Assignee: Pherin Pharmaceuticals, Inc.Inventors: David L. Berliner, Nathan W. Adams, Clive L. Jennings-White
-
Patent number: 6331534Abstract: The invention relates to a method of alleviating pain. The method comprises nasally administering a steroid which is a human vomeropherin, such that the vomeropherin binds to a specific neuroepithelial receptor. The steroid or steroids is/are preferably administered in the form of a pharmaceutical composition containing one or more pharmaceutically acceptable carriers.Type: GrantFiled: August 28, 1997Date of Patent: December 18, 2001Assignee: Pherin Pharmaceuticals, Inc.Inventors: David L. Berliner, Luis Monti-Bloch
-
Patent number: 6242619Abstract: Several 19-nor-pregnanes are provided which have the capacity to neurochemically alter the hypothalamic function in an individual through nasal administration. These pharmaceutically active compounds can be administered by themselves or in the form of a pharmaceutical composition containing one or more pharmaceutically acceptable carriers to produce the desired effect.Type: GrantFiled: August 11, 1998Date of Patent: June 5, 2001Assignee: Pherin Pharmaceuticals, Inc.Inventors: Clive L. Jennings-White, David L. Berliner, Nathan W. Adams
-
Patent number: 6117860Abstract: The invention relates to a method of alleviating the symptoms of PMS and anxiety. The method comprises nasally administering a steroid which is a human vomeropherin, such that the vomeropherin binds to a specific neuroepithelial receptor. The steroid or steroids is/are preferably administered in the form of a pharmaceutical composition containing one or more pharmaceutically acceptable carriers.Type: GrantFiled: July 23, 1997Date of Patent: September 12, 2000Assignee: Pherin Pharmaceuticals, Inc.Inventors: Clive L. Jennings-White, David L. Berliner, Nathan W. Adams, Luis Monti-Bloch
-
Patent number: 5965552Abstract: The invention relates to a method of altering hypothalamic function in an individual. The method comprises nasally administering a human semiochemical, e.g. an Androstane steroid, or a pharmaceutical composition containing a semiochemical, such that the ligand semiochemical binds to a specific neuroepithelial receptor. The steroid or steroids is/are preferably administered in the form of a pharmaceutical composition containing one or more pharmaceutically acceptable carriers. Other embodiments of the invention include pharmaceutical compositions containing the steroids.Type: GrantFiled: December 15, 1998Date of Patent: October 12, 1999Assignee: Pherin Pharmaceuticals, Inc.Inventors: David L. Berliner, Nathan William Adams, Clive L. Jennings-White